12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Albiglutide: Phase III data

The double-blind, international Phase III Harmony 1 trial in 299 Type II diabetics showed that once-weekly subcutaneous 30 mg albiglutide plus Actos pioglitazone with or without metformin met the primary endpoint of reducing HbA1c from baseline to week 52 vs. placebo plus Actos with or without metformin (0.81% vs. 0.05%, p<0.0001). On secondary endpoints, albiglutide plus Actos significantly reduced FPG vs. placebo plus Actos (23.1 mg/dL vs. a gain of 6.4 mg/dL,...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >